Slideset
View More
Review the latest clinical data and expert guidance on management of HER2-positive early-stage breast cancer, including how to assess risk and plan (neo)adjuvant therapy; treat lower- vs higher-risk disease; and optimally manage adverse events associated with HER2-targeted therapy.
Lee Schwartzberg, MD, FACP
Released: June 30, 2020
Get up to date on current and emerging HER2-targeted TKIs and antibody–drug conjugates for HER2-positive metastatic breast cancer across multiple lines of therapy.
Neelima Denduluri, MD, FASCO
Released: June 30, 2020
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.